WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.

ZURICH (Reuters) - Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an ...

Berlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration ...

Ein Jahr später sagte er nun, Bayer strebe keine Pharma- und Biotech-Deals an, deren Volumen zum oberen Rand dieser Spanne hin gehe. Priorität habe stattdessen die Senkung der Schuldenlast.

Bayer's expanded therapies and strategic collaborations in India aim to drive pharmaceutical growth amidst regulatory challenges and pricing pressures.

The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...